Wall Street Zen Upgrades CARGO Therapeutics (NASDAQ:CRGX) to Sell

Key Points

• Wall Street Zen has upgraded CARGO Therapeutics (NASDAQ: CRGX) to a "sell" rating, indicating a bearish outlook on the stock's performance.
• In contrast, Jefferies Financial Group raised its price target for CRGX from $3.70 to $5.00 while maintaining a "hold" rating.
• CARGO Therapeutics has a consensus rating of "Reduce" with an average price target significantly higher at $15.40, despite current trading around $4.47.

CARGO Therapeutics (NASDAQ:CRGX - Get Free Report) was upgraded by equities researchers at Wall Street Zen to a "sell" rating in a research report issued on Friday.

Separately, Jefferies Financial Group increased their price objective on CARGO Therapeutics from $3.70 to $5.00 and gave the stock a "hold" rating in a report on Tuesday, July 8th. Six analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, CARGO Therapeutics has a consensus rating of "Reduce" and an average price target of $15.40.

CARGO Therapeutics Price Performance

Shares of CRGX stock opened at $4.47 on Friday. The stock has a fifty day moving average of $4.44 and a 200 day moving average of $4.23. CARGO Therapeutics has a 52 week low of $3.00 and a 52 week high of $25.45. The firm has a market capitalization of $216.17 million, a price-to-earnings ratio of -0.96 and a beta of 0.30.

Hedge Funds Weigh In On CARGO Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Ascent Group LLC bought a new position in shares of CARGO Therapeutics during the first quarter valued at $43,000. Jane Street Group LLC bought a new position in shares of CARGO Therapeutics during the second quarter valued at $45,000. XTX Topco Ltd bought a new position in shares of CARGO Therapeutics during the first quarter valued at $46,000. Brooklyn Investment Group increased its holdings in shares of CARGO Therapeutics by 512.3% during the first quarter. Brooklyn Investment Group now owns 11,328 shares of the company's stock valued at $46,000 after acquiring an additional 9,478 shares in the last quarter. Finally, Los Angeles Capital Management LLC bought a new position in shares of CARGO Therapeutics during the second quarter valued at $46,000. 93.16% of the stock is currently owned by institutional investors.

About CARGO Therapeutics

CARGO Therapeutics, Inc, a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.